Related Experiment Video

Updated: Jul 12, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials

R Buckstein1, R M Meyer, L Seymour

  • 1Division of Hematology, Odette Cancer Center, Toronto, Ontario.

Current Oncology (Toronto, Ont.)
|August 22, 2007
PubMed

Insights

Sunitinib, an inhibitor of receptor tyrosine kinases like vascular endothelial growth factor (VEGF) receptors, is being investigated for its potential in treating various cancers. Four Phase II trials are evaluating its efficacy in diffuse large cell lymphoma, mesothelioma, cervical, and ovarian cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib (SU11248) is an oral inhibitor targeting receptor tyrosine kinases crucial for tumor growth and angiogenesis.
  • Key targets include vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor receptors (PDGFRA and PDGFRB).
  • Angiogenesis, essential for tumor metastasis, is significantly influenced by VEGF.

Purpose of the Study:

  • To explore the biologic and clinical rationale for Sunitinib's broad-spectrum utility in cancer treatment.
  • To initiate and discuss four Phase II clinical trials investigating Sunitinib in specific cancer types.

Main Methods:

  • Preclinical evaluation of Sunitinib's mechanism of action on receptor tyrosine kinases.
  • Initiation of four Phase II clinical trials under the National Cancer Institute of Canada Clinical Trials Group.
  • Testing Sunitinib in patients with relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer, and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Main Results:

  • Discussion of the biologic rationale supporting Sunitinib's anti-angiogenic and anti-proliferative effects.
  • Clinical rationale for testing Sunitinib across diverse tumor types.
  • The initiation of four distinct Phase II trials signifies a significant step in evaluating Sunitinib's therapeutic potential.

Conclusions:

  • Sunitinib's targeted inhibition of key signaling pathways suggests broad clinical applicability in oncology.
  • The ongoing Phase II trials are critical for determining Sunitinib's efficacy and safety in specific malignancies.
  • Further research is warranted to fully elucidate Sunitinib's role in cancer therapy.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...